. 2020 Mar 4;22:41. doi: 10.1186/s13075-020-2122-5

Table 2.

Comparison of patient background characteristics between a TNFi insensitivity group and a poor response group. For each variable, p values of a simple comparison between the two groups using chi-squared test are shown

Category		TNIi insensitivity		Refractory		Control		p value*
Category		N	%	N	%	N	%	P1	P2	P3
Gender	Female	75	79.8	501	82.9	731	79.9	0.83	0.14	0.34
Gender	Male	19	20.2	103	17.1	184	20.1	0.83	0.14	0.34
Age group	≦50	23	24.5	129	21.4	228	24.9	0.62	0.41	0.48
	51–60	26	27.7	149	24.7	205	22.4
	61–70	19	20.2	165	27.3	246	26.9
	71	26	27.7	161	26.7	236	25.8
Disease duration (year)	< 0.5	22	23.4	75	12.4	165	18.0	0.45	< 0.01^†	0.01^†
	0.5–2	31	33.0	163	27.0	284	31.0
	2–5	17	18.1	117	19.4	159	17.4
	≥ 5	24	25.5	247	40.9	306	33.4
DAS28-CRP at week 0	< 3.2	3	3.2	6	1.0	43	4.7	< 0.01^†	< 0.01^†	0.18
	3.2–5.1	12	12.8	94	15.6	259	28.3
	> 5.1	79	84.0	502	83.1	613	67.0
RF positivity**	Negative	25	26.6	127	21.0	240	26.2	0.95	0.02^†	0.24
RF positivity**	Positive	69	73.4	473	78.3	673	73.6	0.95	0.02^†	0.24
Use of GC	No	66	70.2	393	65.1	708	77.4	0.13	< 0.01^†	0.30
Use of GC	Yes	28	29.8	211	34.9	207	22.6	0.13	< 0.01^†	0.30
Dose of MTX (mg/week)	0	13	13.8	81	13.4	83	9.1	0.22	< 0.01^†	0.47
	1–6	10	10.6	74	12.3	79	8.6
	7–9	22	23.4	189	31.3	218	23.8
	10–15	32	34.0	176	29.1	294	32.1
	> 15	17	18.1	84	13.9	241	26.3
Failure in > 2 csDMARDs	No	44	46.8	301	49.8	365	39.9	0.16	< 0.01^†	0.66
Failure in > 2 csDMARDs	Yes	50	53.2	303	50.2	550	60.1	0.16	< 0.01^†	0.66
Entry phase	I	29	30.9	287	47.5	327	35.7	0.11	< 0.01^†	< 0.01^†
	II	24	25.5	169	28.0	179	19.6
	III	22	23.4	95	15.7	287	31.4
Drug type	IFX	2	2.1	11	1.8	12	1.3	0.77	< 0.01^†	< 0.01^†
	ETN	17	18.1	42	7.0	110	12.0
	ADA	5	5.3	55	9.1	55	6.0
	GLM	22	23.4	234	38.7	186	20.3
	CZP	67	71.3	315	52.2	674	73.7

*P1, comparison between control and insensitivity; P2, comparison between control and refractory; P3, comparison between insensitivity and refractory

**RF > 20 IU/mL was defined as positive

^†p < 0.05

DAS28 disease activity score for 28 joints, CRP c-reactive protein, MTX methotrexate, IFX infliximab, ETA etanercept, ADA adalimumab, GLM golimumab, CZP certolizumab, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs